Vicarious Surgical (NYSE:RBOT) and Bone Biologics (NASDAQ:BBLG) Head-To-Head Analysis

Vicarious Surgical (NYSE:RBOT) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

Profitability

This table compares Vicarious Surgical and Bone Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-81.46%	-63.62%
Bone Biologics	N/A	-124.71%	-111.64%

Analyst Ratings

This is a summary of current recommendations and price targets for Vicarious Surgical and Bone Biologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	0	2	0	0	2.00
Bone Biologics	0	0	0	0	0.00

Vicarious Surgical currently has a consensus target price of $10.25, suggesting a potential downside of 33.72%. Given Vicarious Surgical’s stronger consensus rating and higher possible upside, research analysts plainly believe Vicarious Surgical is more favorable than Bone Biologics.

Insider & Institutional Ownership

47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 11.7% of Vicarious Surgical shares are held by insiders. Comparatively, 7.5% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Vicarious Surgical has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Earnings and Valuation

This table compares Vicarious Surgical and Bone Biologics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$71.07 million	($10.29)	-1.50
Bone Biologics	N/A	N/A	-$8.95 million	N/A	N/A

Summary

Vicarious Surgical beats Bone Biologics on 7 of the 8 factors compared between the two stocks.

About Vicarious Surgical

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.